BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 34867818)

  • 1. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.
    Pereira M; Matuszewska K; Jamieson C; Petrik J
    Front Endocrinol (Lausanne); 2021; 12():772349. PubMed ID: 34867818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basics of immunotherapy for epithelial ovarian cancer.
    Bund V; Azaïs H; Bibi-Triki S; Lecointre L; Betrian SB; Angeles MA; Eberst L; Faller E; Boisramé T; Bendifallah S; Akladios C; Deluche É;
    J Gynecol Obstet Hum Reprod; 2022 Feb; 51(2):102283. PubMed ID: 34875397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
    Chodon T; Lugade AA; Battaglia S; Odunsi K
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptation of metabolism to multicellular aggregation, hypoxia and obese stromal cell incorporation as potential measure of survival of ovarian metastases.
    Compton SLE; Pyne ES; Liu L; Guinan J; Shea AA; Grieco JP; Frisard MI; Schmelz EM
    Exp Cell Res; 2021 Feb; 399(1):112397. PubMed ID: 33338477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.
    Rodriguez GM; Galpin KJC; Cook DP; Yakubovich E; Maranda V; Macdonald EA; Wilson-Sanchez J; Thomas AL; Burdette JE; Vanderhyden BC
    Cancer Res Commun; 2022 Jun; 2(6):417-433. PubMed ID: 36311166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.
    Schoutrop E; Moyano-Galceran L; Lheureux S; Mattsson J; Lehti K; Dahlstrand H; Magalhaes I
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):207-223. PubMed ID: 35395389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
    Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
    Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies.
    Klemba A; Bodnar L; Was H; Brodaczewska KK; Wcislo G; Szczylik CA; Kieda C
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
    Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
    Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
    Crestani A; Benoit L; Touboul C; Pasquier J
    Gynecol Oncol; 2020 Oct; 159(1):285-294. PubMed ID: 32732012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.
    Capellero S; Erriquez J; Melano C; Mesiano G; Genta S; Pisacane A; Mittica G; Ghisoni E; Olivero M; Di Renzo MF; Aglietta M; Sangiolo D; Valabrega G
    Sci Rep; 2020 Apr; 10(1):6478. PubMed ID: 32296104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission.
    Tyagi K; Mandal S; Roy A
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188563. PubMed ID: 33971276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy.
    Wang Y; Zhang L; Bai Y; Wang L; Ma X
    Front Immunol; 2022; 13():1036298. PubMed ID: 36341388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
    Flores I; Hevia D; Tittarelli A; Soto D; Rojas-Sepúlveda D; Pereda C; Tempio F; Fuentes C; Falcón-Beas C; Gatica J; Falcón-Beas F; Galindo M; Salazar-Onfray F; González FE; López MN
    J Immunol Res; 2019; 2019():9631515. PubMed ID: 31886313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
    Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 17. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
    Grabosch S; Bulatovic M; Zeng F; Ma T; Zhang L; Ross M; Brozick J; Fang Y; Tseng G; Kim E; Gambotto A; Elishaev E; P Edwards R; Vlad AM
    Oncogene; 2019 Mar; 38(13):2380-2393. PubMed ID: 30518877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
    Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
    Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cancer-associated mesothelial cells in the progression and therapy of ovarian cancer.
    Zheng A; Wei Y; Zhao Y; Zhang T; Ma X
    Front Immunol; 2022; 13():1013506. PubMed ID: 36268019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.